Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Price Target of $4.96

Humacyte, Inc. (NASDAQ:HUMA) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $4.96.

A number of equities analysts have recently issued reports on the company. Williams Trading set a $1.00 target price on Humacyte in a research note on Friday, October 16th. HC Wainwright restated a “buy” rating on shares of Humacyte in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Barclays raised Humacyte to a “hold” rating in a report on Wednesday, October 7th. Finally, Benchmark cut their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the stock. HBK Investments L P purchased a new position in shares of Humacyte in the 2nd quarter valued at about $617,000. Miramontes Capital LLC acquired a new stake in shares of Humacyte in the second quarter valued at about $85,000. Alyeska Investment Group L.P. acquired a new stake in shares of Humacyte in the second quarter valued at about $4,700,000. Beacon Pointe Advisors LLC purchased a new stake in Humacyte during the second quarter worth about $28,000. Finally, Stonepine Capital Management LLC purchased a new stake in Humacyte during the second quarter worth about $180,506. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Stock Down 0.1%

Shares of Humacyte stock opened at $0.47 on Friday. Humacyte has a 52-week low of $0.34 and a 52-week high of $1.70. The company’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.81. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The firm had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Analysts predict that Humacyte will post -0.40 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.